SCHEMBL856193

SCHEMBL856193

Cc1nc(Cl)c2c(n1)CCC(C)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 4/20 0.48
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
GLA P06280 1/20 0.40
LMNA P02545 2/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
HRH2 P25021 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
PDK1 Q15118 1/20 0.37
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 2/20 0.34
CCNC P24863 1/20 0.34
HTT P42858 1/20 0.34
CDK8 P49336 1/20 0.34
CDK19 Q9BWU1 1/20 0.34
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30680099 0.84 ALDH1A1 (0.42) ALDH1A1KDM4ECYP1A2CYP2C19GLA
SCHEMBL24373917 0.84 ALDH1A1 (0.42) ALDH1A1KDM4ECYP1A2CYP2C19GLA
SCHEMBL856217 0.78 NOS3 (0.35) ALDH1A1KDM4EHTR2AHTR2CHTR2B
SCHEMBL858789 0.71 ALDH1A1 (0.38) ALDH1A1KDM4ECYP1A2CYP2C19GLA
SCHEMBL1069076 0.71 KDM4E (0.41) KDM4EMAPK1HSD17B10HTTACHE
SCHEMBL3106221 0.71 MAPK1 (0.44) ALDH1A1KDM4ECYP1A2CYP2C19LMNA
SCHEMBL30666826 0.70 PDE10A (0.31)
SCHEMBL18512800 0.70 ADRA1A (0.31)
SCHEMBL30680105 0.69 LMNA (0.38) ALDH1A1KDM4ECYP1A2CYP2C19GLA
SCHEMBL24373918 0.69 LMNA (0.38) ALDH1A1KDM4ECYP1A2CYP2C19GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3395/4885KDM4E 610/4885CYP1A2 997/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3533/4885KDM4E 361/4885CYP1A2 878/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3049/4885KDM4E 760/4885CYP1A2 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.